Coagulation Factor Deficiency Global Market Report 2025

The coagulation factor deficiency market size has grown strongly in recent years. It will grow from $4.58 billion in 2024 to $4.94 billion in 2025 at a compound annual growth rate (CAGR) of 8%. The growth during the historic period was driven by the rising prevalence of hemophilia, the introduction of recombinant clotting factors, increased awareness of coagulation disorders, advancements in diagnostic capabilities, government support for rare diseases, the development of prophylactic therapies, the expansion of patient registries, and growing investments in biotechnology.

The coagulation factor deficiency market size is expected to see strong growth in the next few years. It will grow to $6.64 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The projected growth during the forecast period is driven by the increasing adoption of gene therapies, a stronger focus on personalized medicine, the rising prevalence of coagulation disorders, expanding treatment access in emerging markets, and the integration of digital health solutions alongside continuous advancements in biomanufacturing technologies. Key trends include the emergence of gene editing technologies such as CRISPR, the development of long-acting recombinant factors, innovations in gene therapy delivery systems, wearable coagulation monitoring devices, AI-driven treatment optimization, advancements in point-of-care diagnostic tools, nanoparticle-based drug delivery, plasma-free recombinant product development, biosimilar innovation, and the integration of precision medicine approaches.

The rising incidences of blood-related disorders are expected to drive the growth of the coagulation factor deficiency market. Blood-related disorders encompass conditions that affect the production, function, or composition of blood cells, platelets, or plasma, leading to complications such as anemia, clotting issues, or immune system deficiencies. The increase in these disorders is attributed to factors such as aging populations, genetic predispositions, rising awareness, environmental influences, lifestyle changes, the growing burden of chronic diseases, and advancements in diagnostic technologies that enable earlier detection. Coagulation factor deficiency plays a vital role in managing blood-related disorders by supplying essential clotting factors needed to prevent or control excessive bleeding in conditions such as hemophilia, where the body's natural ability to form blood clots is impaired. For example, in September 2024, the Leukemia and Lymphoma Society, a US-based professional organization, reported that every three minutes, one person in the US is diagnosed with leukemia, lymphoma, or myeloma. In 2024, an estimated 187,740 individuals were diagnosed with these cancers, accounting for 9.4% of the projected 2,001,140 new cancer cases in the US. Additionally, in May 2024, NHS England, a UK-based government-funded healthcare system, revealed that approximately 17,000 people in England are living with sickle cell disease, an inherited blood disorder, with around 250 new cases diagnosed annually. As a result, the increasing prevalence of blood-related disorders is fueling the growth of the coagulation factor deficiency market.

Leading companies in the coagulation factor deficiency market are focusing on developing groundbreaking therapies, such as one-time gene therapy, to offer long-term or potentially curative solutions for patients with bleeding disorders such as hemophilia, thereby reducing the need for lifelong infusions of clotting factors. One-time gene therapy involves introducing or modifying genetic material within a patient's cells to treat or cure a disease, with the goal of providing sustained or permanent therapeutic effects after a single treatment. For instance, in April 2024, Pfizer Inc., a US-based pharmaceutical and biotechnology company, announced that the U.S. Food and Drug Administration (FDA) had approved BEQVEZ (fidanacogene elaparvovec-dzkt) for the treatment of adults with moderate to severe hemophilia B who currently rely on factor IX (FIX) prophylaxis therapy. This one-time adeno-associated virus (AAV)-based gene therapy is designed to introduce a functional copy of the FIX gene encoding a high-activity FIX variant into transduced cells. For patients with hemophilia B, this therapy enables them to produce FIX independently, eliminating the need for frequent FIX infusions.

In March 2024, ReciBioPharm, a US-based contract development and manufacturing organization (CDMO) in the pharmaceutical industry, partnered with GeneVentiv Therapeutics to advance the development of an adeno-associated virus (AAV)-based universal gene therapy for hemophilia, marking the first treatment for hemophilia patients with inhibitors. Through this collaboration, ReciBioPharm will expedite the development of the technology using its state-of-the-art AAV manufacturing platform. GeneVentiv Therapeutics, a US-based preclinical gene therapy company, is working to pioneer innovative treatments that could revolutionize hemophilia management.

Major players in the coagulation factor deficiency market are Pfizer Inc., F Hoffmann-La Roche Ltd., Bayer HealthCare Pharmaceuticals, Sanofi Genzyme, Novo Nordisk A/S, Baxter International Inc., CSL Behring LLC, Grifols S.A., Octapharma AG, Takeda Pharmaceutical Company Limited, Swedish Orphan Biovitrum AB, GC Biopharma Co. Ltd., Alnylam Pharmaceuticals Inc., Opko Health Inc., Kedrion Biopharma Inc., Shanghai RAAS Blood Products Co. Ltd., LFB S.A., Biotest AG, Spark Therapeutics Inc., Biogen Inc., Sangamo Therapeutics Inc., Centessa Pharmaceuticals Inc.

North America was the largest region in the coagulation factor deficiency market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in coagulation factor deficiency report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the coagulation factor deficiency market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Coagulation factor deficiency is a condition in which the body lacks one or more essential clotting factors required for proper blood coagulation, resulting in prolonged bleeding or difficulty in stopping bleeding. Treatment involves the use of clotting factor concentrates and other therapies to manage and prevent bleeding episodes in individuals with conditions such as hemophilia.

The primary product types for treating coagulation factor deficiency include recombinant coagulation factor concentrates, plasma-derived coagulation factor concentrates, biologics, desmopressin, and others. Recombinant coagulation factor concentrates are lab-engineered proteins designed to replace missing clotting factors in affected patients. The deficiency types include hemophilia A, hemophilia B, von Willebrand disease, factor XI deficiency, factor XIII deficiency, and others. These treatments are utilized across various healthcare settings, including hospitals, clinics, home care, and more.

The coagulation factor deficiency market research report is one of a series of new reports that provides coagulation factor deficiency market statistics, including coagulation factor deficiency industry global market size, regional shares, competitors with a coagulation factor deficiency market share, detailed coagulation factor deficiency market segments, market trends and opportunities, and any further data you may need to thrive in the coagulation factor deficiency industry. This coagulation factor deficiency market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The coagulation factor deficiency market consists of sales of factor VIII concentrates, prothrombin complex concentrates, and fresh frozen plasma (FFP). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.